Breaking News, Collaborations & Alliances

VectorY Enters Collaboration with Wageningen University

Will work together to develop novel baculovirus-based technologies for the production of safe & affordable AAV gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor

VectorY Therapeutics, a biotech company focusing on the development of gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, is collaborating with Wageningen University to develop novel baculovirus-based technologies for the production of safe and affordable AAV gene therapies.   VectorY, together with its partner Wageningen University, is making a strategic investment in the gene therapies of the future, by developing a production...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters